Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07205887 · ClinicalTrials.gov registry record · Phase 2
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
A Phase 2 study of Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO), sponsored by EyeBiotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT07205887: Recruiting Phase 2 study of Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO), sponsored by EyeBiotech.
NCT07205887 is a Phase 2 study of Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO) that is actively recruiting participants, run by EyeBiotech. The registered enrollment target is 160 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07205887, a Phase 2 study of Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO), is actively recruiting participants, sponsored by EyeBiotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion. All participants in the study will receive a total of 3 injections of EYE103 into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.
Primary Outcome
Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Conditions Studied
Interventions
- DRUG EYE103
- DRUG Aflibercept 2.0 mg
Study Locations (20)
California
- Glendale, California - Glendale
- Glendale, CA - Glendale
- Modesto, California - Modesto
- Mountain View, California - Mountain View
- Sacramento, CA - Sacramento
- Sactamento, California - Sacramento
- Sacramento, California - Sacramento
- Santa Ana, California - Santa Ana
Arizona
- Scottsdale, Arizona - Scottsdale
- Scottsdale, AZ - Scottsdale
Florida
- Fort Lauderdale, Florida - Fort Lauderdale
- Fort Lauderdale, FL - Fort Lauderdale
Illinois
- Lemont, Illinois - Lemont
- Lemont, IL - Lemont
Maryland
- Hagerstown, Maryland - Hagerstown
- Hagerstown, MD - Hagerstown
Mississippi
- Madison, Mississippi - Madison
- Madison, MS - Madison
New Jersey
- Bloomfield, New Jersey - Bloomfield
- Bloomfield, NJ - Bloomfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT07205887 shows while recruiting
NCT07205887 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 2 conditions, with Neovascular Age-Related Macular Degeneration (NVAMD) appearing as the primary indexed condition, and to 2 interventions - of which EYE103 is the first listed.
NCT07205887 names 20 study sites across 7 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07205887 about?
NCT07205887 is a clinical study titled "A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO". EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomized (...
What is the current status of trial NCT07205887?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-09-12. Estimated completion is 2028-06-30.
What conditions does trial NCT07205887 study?
This clinical trial studies the following conditions: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO).
What interventions are being tested in trial NCT07205887?
The interventions under investigation include: EYE103 (DRUG), Aflibercept 2.0 mg (DRUG).
Who is sponsoring clinical trial NCT07205887?
This trial is sponsored by EyeBiotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07205887 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-Related Macular Degeneration (NVAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07205887's enrollment target sits among peer trials
160 422nd of 2000 higher than 1,560 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI